INDIAN SOCIETY OF HYPERTENSION

Hypertension Journal

Review Article

Hypertensive Encephalopathy: A Comprehensive Review

Mohd Saalim[1], Uzma Ali[2*]

[1]Department of Biochemistry, King George's Medical University, Lucknow, UP, India
[2]Department of Cardiology, Orient Hospital, Mangalore, Karnataka, India

Abstract

The handling of hypertensive encephalopathy - an urgent medical situation marked by sharp neurological symptoms caused due to severe hypertension-driven brain malfunction - is critical. This overview aims to dissect extensively, the mechanisms causing the disease, the various clinical signs it reflects, how it is typically investigated, and the most efficient management methods. Bringing into focus how patients fare, we highlight the most recent scholarly studies and pragmatic guidelines. As such, we aim to deepen the understanding of healthcare professionals about hypertensive encephalopathy in order to optimize patient treatment. Overall, a multidisciplinary approach involving neurologists, intensivists, and other specialists is often required to effectively manage hypertensive encephalopathy. Early recognition, accurate diagnosis, and aggressive blood pressure control are key elements in optimizing outcomes and preventing long-term complications in patients with hypertensive encephalopathy.

Keywords: Hypertensive Encephalopathy, Blood Pressure Monitoring, Sodium Nitroprusside, Labetalol, Esmolol, Hydralazine, Enalaprilat, Phentolamine.

DOI: 10.61081/htnj/23v9i205

Introduction

Encephalopathy, as a product of hypertension, though less frequently occurring, stands as a subtype of hypertensive crises. The indication progression of hypertensive encephalopathy normally begins with headaches, nausea, and vomiting, escalating to neurological disturbances like agitation, disorientation, seizure episodes, and, in extreme cases, even coma.

Triggered health crises can range from cardiac ischemic incidents, pulmonary edema, acute kidney failure, aortic rupture, and retinopathy to complications like eclampsia and encephalopathy. It's often identified post facto - the diagnosis coming only after noticeable alleviation in the patient's symptoms upon achieving blood pressure reduction, and upon eliminating other potential neurological disorder sources.

A hypertensive crisis connotes a situation that potentially threatens life, primarily attributable to substantial blood pressure spikes instigating damage to various vital organs. The condition typically manifests signs of cerebral swelling ensuing from an intense hypertension bout. Timely managed hypertension often leads to full reversibility of encephalopathy symptoms.[1]

"Specifically, hypertensive emergencies can rapidly manifest into hypertensive encephalopathy, marked by transient and migratory neurological signs. On the other hand, despite severely heightened blood pressure levels, hypertensive urgency shows no signs of organ damage, allowing a more gradual reduction in pressure levels typically over 24 to 48 hours.

In cases with dangerously high blood pressure, termed 'hypertensive crisis', the situation becomes severe if the pressure results in damage to vital organs like the brain, heart, or kidneys. This is known as a hypertensive emergency and requires a swift and significant blood pressure reduction within hours.

However, in managing patients displaying these symptoms, it becomes essential to rule out other systemic diseases or cerebrovascular events. That's because they can present similar clinical manifestations. For most cases, immediate medical intervention can reverse these symptoms."

Corresponding author
Department of Cardiology, Orient Hospital, Mangalore, Karnataka, India,
Email: Uzma_ali_95@hotmail.com

Pathophysiology

The pathology of hypertensive encephalopathy pivots around a collection of neurological signs caused by unregulated, intense

hypertension. Central to this health condition's pathophysiology is the breaching of normal cerebral autoregulation processes. The maintenance of brain perfusion across various systemic blood pressure levels is ordinarily managed by these mechanisms, known as the cerebral autoregulation band. However, in circumstances of hypertension that exceed this autoregulation band, the compensatory increase in brain perfusion could inadvertently give rise to cerebral edema.[1-4]

The brain has an impressive capability for maintaining a consistent blood flow even when systemic arterial pressure fluctuates. This principle operates within distinct limits, involving the pressure facilitating blood flow in the brain and the standard pressure within the arteries. For individuals in good health, the pressure governing cerebral blood flow ranges from 50 to 150 mm Hg, and the common arterial pressure usually lies between 60 to 160 mm Hg. Significantly, the cerebral pressure can be ascertained by deducting the brain's internal pressure from the mean arterial pressure.[5]

In essence, this hypertensive-induced hyperperfusion may spur the release of vasoactive agents and inflammatory messengers, contributing further to the destabilization of the cerebral-vascular barrier - blood-brain barrier (BBB). This destabilization can lead to vasogenic edema, a common entity in hypertensive encephalopathy, which typically presents symptoms like headaches, alterations in consciousness, and potential seizure incidents.

The progression and characteristics of this pathological condition are partly determined by the rapidity of blood pressure increase and the differences in cerebral autoregulation abilities between individuals.[6] This variability explains why similar blood pressure levels might lead to hypertensive encephalopathy in one person and yet be tolerable in another.[7,8]

To simplify this, hypertensive encephalopathy is a neurological condition caused by extreme, unmanaged high blood pressure. The key aspect of this disease relates to the failure of the cerebral autoregulation system, which normally controls blood flow through the brain. If hypertension exceeds the limits that this system can handle, this can lead to damaging over-perfusion and consequent cerebral edema.

Furthermore, this condition can prompt the discharge of certain compounds that affect blood vessels and the inflammatory response, further affecting the blood-brain barrier (BBB).[9] Consequently, vasogenic edema can develop, leading to typical symptoms seen in hypertensive encephalopathy, including headaches, mental status changes, and possible seizures.

Ultimately, the commencement and intensity of this condition can differ among individuals. This variation depends on how rapidly blood pressure rises and individual cerebral autoregulation capabilities, meaning the same high blood pressure can have different effects on different individuals.[2,7,10,11]

Clinical Presentation

Hypertensive encephalopathy presents a range of clinical manifestations linked to severely elevated blood pressure. One common symptom is a severe and often persistent throbbing headache. Additionally, patients may exhibit alterations in mental status, characterized by confusion, disorientation, and potentially agitation or restlessness. Visual disturbances, including blurred vision and visual field deficits, can also occur.[12,13] Another potential consequence of hypertensive encephalopathy is the development of seizures, which can have varying levels of severity. Some individuals may experience focal neurological deficits, such as weakness or abnormal sensations in specific body areas. In severe cases, hypertensive encephalopathy can progress to a state of unconsciousness or coma.[14-16]

Diagnostic Approaches

Neuroimaging is pivotal in recognizing and evaluating hypertensive encephalopathy. Techniques such as computerized tomography scan (CT scan) and magnetic resonance imaging (MRI) can be considered to pinpoint potential brain abnormalities causing neurological manifestations or to exclude ailments like ischemic stroke or intracerebral bleeding.

While MRI is more sensitive in detecting brain edema, CT is often more accessible and provides quicker results, making it valuable in excluding certain intracranial abnormalities. T2-weighted MRI, in particular, can precisely locate areas of Cerebral edema that is linked to hypertensive encephalopathy and can be identified as either posterior reversible encephalopathy syndrome (PRES) or hypertensive brainstem encephalopathy. It's worth noting that the occurrence of bilateral white matter edema specifically in the posterior cerebral hemispheres serves as a significant indication of PRES.

In summary, neuroimaging techniques like CT and MRI are essential in the evaluation of hypertensive encephalopathy, allowing for the identification of brain lesions and distinguishing specific subtypes based on characteristic findings like posterior cerebral hemispheric edema.[17]

History and Physical Examination

Obtaining a comprehensive drug history is crucial in order to identify any antihypertensive medications that have been previously used. The diagnosis of hypertensive encephalopathy relies predominantly on a comprehensive physical exam and history assessment. Patients who develop hypertensive encephalopathy typically have chronic uncontrolled hypertension and may have recently stopped taking their antihypertensive medication. It is important to thoroughly assess patients who present with elevated blood pressure along with symptoms such as altered mental status, visual abnormalities, headache, or seizures.[18]

In the majority of cases, patients diagnosed with hypertensive encephalopathy exhibit blood pressure levels exceeding 220/120 mm Hg. It is crucial to evaluate patients with signs of organ damage, which can occur during a hypertensive emergency. A thorough examination of the chest may uncover signs of cardiac dysfunction, such as extra heart sounds or the presence of pulmonary edema, which is characterized by rales heard during lung auscultation.[19] Performing a fundoscopy examination can reveal retinal hemorrhages and papilledema, which are severe signs of hypertensive retinopathy. Conducting a comprehensive neurological examination is essential for identifying any focal or

non-focal deficits, and it may be necessary to consider alternative differential diagnoses for conditions that present with similar symptoms.[20]

Blood Pressure Monitoring:

Blood pressure monitoring is a crucial aspect of managing patients with hypertensive encephalopathy. Continuous and accurate monitoring allows healthcare providers to assess the effectiveness of treatment interventions and make necessary adjustments.

Several authentic sources provide guidance on blood pressure monitoring in hypertensive encephalopathy. The American Heart Association (AHA) provides recommendations on the acute management of hypertensive emergencies, including encephalopathy. According to the AHA guidelines, frequent blood pressure measurements should be conducted initially, typically every 5 to 15 minutes, to carefully monitor and control blood pressure levels. It is important to aim for a gradual reduction in blood pressure to avoid abrupt decreases, which can potentially worsen cerebral ischemia.

The European Society of Hypertension (ESH) also provides guidelines on the management of hypertensive emergencies. The ESH recommends continuous blood pressure monitoring in hypertensive encephalopathy, especially in critically ill patients. They emphasize the need for promptly identifying and treating elevated blood pressure to prevent further brain damage.

These guidelines, along with other reputable sources like textbooks, review articles, and clinical practice guidelines, provide comprehensive information on the appropriate techniques and frequency of blood pressure monitoring in hypertensive encephalopathy. It is always recommended to refer to these authoritative sources for detailed and up-to-date information on blood pressure monitoring in specific clinical situations.[21,22]

Laboratory Tests

Baseline laboratory tests, such as a complete blood count (CBC), comprehensive metabolic panel (CMP), assessment of kidney function, and additional optional tests, form an essential component of the diagnostic process for hypertensive encephalopathy. These tests are crucial for evaluating underlying causes or potential complications associated with the condition. A comprehensive assessment of blood parameters, electrolyte levels, renal function, and optional tests for underlying causes or complications assists healthcare professionals in understanding the severity of the condition and tailoring appropriate treatment strategies. Timely diagnosis and intervention are vital to ensure optimal patient outcomes and reduce the risk of long-term complications associated with hypertensive encephalopathy.

The diagnostic evaluation of hypertensive encephalopathy relies heavily on two important tests: the Complete Blood Count (CBC) and the Comprehensive Metabolic Panel. The CBC examines the levels of red and white blood cells, along with hemoglobin levels and platelet counts. These tests play a critical role in the diagnostic workup of hypertensive encephalopathy, providing insights into potential abnormalities such as anemia or infection. CMP evaluates electrolyte levels (e.g., sodium, potassium), renal function parameters, liver function markers, and blood glucose levels. These tests help identify electrolyte abnormalities, renal dysfunction, liver dysfunction, or underlying metabolic disorders that may contribute to hypertensive encephalopathy.

Renal function assessment is crucial in patients with hypertensive encephalopathy. Measuring serum creatinine levels provides an indication of kidney function. Additionally, the calculated estimated glomerular filtration rate (eGFR) helps determine the extent of renal impairment. Impaired kidney function can contribute to hypertension and its complications. Serial monitoring of kidney function aids in evaluating the progression as well as the response to treatment.

In certain cases, additional tests may be warranted to assess for potential underlying causes or complications related to hypertensive encephalopathy. Urinalysis helps identify any abnormalities such as proteinuria or hematuria, which may suggest renal involvement.

The diagnostic evaluation of hypertensive encephalopathy relies heavily on two important tests: the Complete Blood Count (CBC) and the Comprehensive Metabolic Panel. The CBC examines the levels of red and white blood cells, along with hemoglobin levels and platelet counts. These tests play a critical role in the diagnostic workup of hypertensive, which can contribute to or complicate hypertensive encephalopathy.

Neuroimaging

Neuroimaging plays a crucial role in the diagnostic approach to hypertensive encephalopathy. Ordering neuroimaging studies, such as non-contrast head computed tomography (CT) or magnetic resonance imaging (MRI), can provide valuable insights into the presence of acute ischemic or hemorrhagic stroke, cerebral edema, and other structural abnormalities.

Due to their widespread availability, quick acquisition time, and ability to identify acute hemorrhage, non-contrast head CT scans are frequently preferred as the initial imaging method for evaluating hypertensive encephalopathy. CT scans can reveal signs of increased intracranial pressure, such as midline shift or effacement of cerebral sulci, which indicate brain swelling. Additionally, CT imaging may detect white matter changes, indicative of cerebral ischemia or small infarcts associated with hypertensive encephalopathy.

In cases where a more detailed evaluation is required, utilizing magnetic resonance imaging (MRI) can offer further insights into the structural changes occurring in the brain. MRI has superior sensitivity in identifying acute ischemic and hemorrhagic strokes, as well as differentiating between various types of brain edema. It can also help visualize white matter abnormalities, assess for potential underlying vascular malformations, and rule out other structural causes that may mimic hypertensive encephalopathy.[23]

Other Investigations

Additional investigations may be required in the diagnostic evaluation of hypertensive encephalopathy to identify underlying causes or associated complications. These investigations may include an electrocardiogram (ECG) to assess for cardiac

abnormalities, an echocardiogram to evaluate cardiac function, or a carotid duplex ultrasound to examine for potential narrowing of the carotid arteries. These tests help determine if any abnormalities in the heart or blood vessels contribute to the development of hypertensive encephalopathy. Secondary hypertension is a condition characterized by high blood pressure that is caused by an underlying medical condition, is suspected, further diagnostic tests may be necessary. This could involve renal imaging to evaluate the kidneys for any structural abnormalities or hormone assays to assess specific hormone levels that can affect blood pressure regulation. In some cases, genetic testing might be recommended to identify any genetic factors contributing to hypertension. These additional investigations help determine the underlying cause of high blood pressure and guide appropriate treatment strategies.

Differential Diagnosis[17]

- Ischemic stroke
- Intracerebral hemorrhage
- Intracranial tumor
- Occult brain trauma
- Acute toxic metabolic encephalopathy
- Central venous thrombosis

Management

The management of a hypertensive emergency and hypertensive encephalopathy is a critical aspect of clinical care that aims at stabilizing blood pressure and mitigating the risk of acute end-organ damage. Prompt identification and appropriate treatment are key to preventing significant morbidity and mortality associated with these severe conditions. The strategy integrates judicious use of antihypertensive medications to control abnormally high blood pressure and targeted therapies to address specific symptoms and pathologies, such as neurologic abnormalities in hypertensive encephalopathy. Aligning with the urgency of the situation, the delivery of care requires careful clinical judgment to balance immediate blood pressure reduction while avoiding potential complications related to overly aggressive therapy. Ultimately, the goal of managing these hypertensive conditions is to restore hemodynamic stability and preserve organ function, thereby improving patient outcomes.

In the category of nitrates, substances like nitroprusside and nitroglycerin are utilized, which contribute nitric oxide. This oxide initiates widening of blood vessels, Cyclic GMP (cGMP) plays a crucial role in regulating the dilation of both arterioles and veins. This process involves the activation of potassium channels, which are sensitive to calcium and located in the cell membrane.[10]

Sodium Nitroprusside

Sodium nitroprusside, once introduced through intravenous infusion, exhibits rapidly-acting properties, beginning to take effect within a minute. Likewise, upon cessation, its effects dissipate rapidly, usually within a span of 10 minutes or less. Given its potential to cause a pronounced and abrupt reduction in blood pressure, it necessitates frequent monitoring.

The recommended starting dose for nitroprusside is typically within the range of 0.25 to 0.5 mcg/kg per minute. Based on the patient's response, this dosage can be gradually increased, reaching a maximum of 8 to 10 mcg/kg per minute. However, it is generally advised to use these higher doses for a maximum duration of 10 minutes or to limit their utilization.[11]

Nitroglycerin:

Nitroglycerine is an intravenous medication with similarities to nitroprusside. However, it mainly causes **venodilation** rather than arteriolar dilation. While its antihypertensive efficacy is relatively lower compared to other hypertensive emergency drugs, it can be beneficial for patients with symptomatic coronary disease or hypertension following coronary bypass. To prevent tachyphylaxis, prolonged infusions are generally avoided.

The initial dose of nitroglycerin is typically 5 mcg/min, which can be adjusted as needed, but should not exceed 100 mcg/min. The onset of action for nitroprusside typically takes place within a timeframe of 2 to 5 minutes. Its effects are relatively short-lasting, with a duration of action lasting around 5 to 10 minutes. It is important to be aware of potential side effects, such as headache (caused by direct vasodilation) and tachycardia (resulting from sympathetic activation). Unlike nitroprusside, nitroglycerin does not lead to cyanide accumulation. However, methemoglobinemia (a rise in methemoglobin levels) has been reported in some patients receiving nitroglycerin infusions for prolonged periods (>24 hours).

The onset of action for nitroprusside typically takes place within a timeframe of 2 to 5 minutes. Its effects are relatively short-lasting, with a duration of action lasting around 5 to 10 minutes. It is important to be aware of potential side effects, such as headache (caused by direct vasodilation) and tachycardia (resulting from sympathetic activation).[7]

Clevidipine:

Clevidipine is an intravenous dihydropyridine calcium channel blocker recommended for the management of severe hypertension. It is unique in that it has an ultra-short half-life of 5 to 15 minutes due to hydrolysis by serum esterases. Clevidipine effectively lowers blood pressure without affecting cardiac filling pressures; however, it may cause reflex tachycardia.[1,12] Comparatively, studies have shown its effectiveness to be similar or superior to nitroglycerin, nitroprusside, and nicardipine in acutely hypertensive patients during and after cardiac surgery.[13]

Some contraindications for clevidipine include severe aortic stenosis (due to an increased risk of severe hypotension), disordered lipid metabolism (as it is administered in a lipid-based emulsion), and known allergies to soy or eggs (as they are used in emulsion production).

The recommended initial dose of clevidipine is 1-mg/hour, which can be titrated up to a maximum of 21 mg/hour as needed.

Nicardipine

Nicardipine is an intravenous calcium channel blocker belonging to

the dihydropyridine class, similar to nifedipine. It is administered as an infusion, starting with an initial dose of 5 mg/hour, which may be increased up to a maximum of 15 mg/hour. Clinical studies have demonstrated that nicardipine has a similar antihypertensive effect to nitroprusside but with a more favorable safety profile.[14]
One notable limitation of nicardipine is its longer onset of action, which means that it cannot be rapidly titrated. Additionally, it has a longer elimination half-life in the bloodstream, spanning approximately three to six hours.

Fenoldopam

Unlike other parenteral antihypertensive agents, fenoldopam is a peripheral dopamine-1 receptor agonist that simultaneously lowers blood pressure while maintaining or increasing kidney perfusion.[15] Fenoldopam can be particularly advantageous in patients with impaired kidney function, as it may enhance glomerular filtration rate, urine output, and sodium excretion compared to nitroprusside.[16,17] The initial dose of fenoldopam is typically 0.1-mcg/kg per minute, with the option to titrate the dosage every 15 minutes up to 1.6 mcg/kg per minute based on the individual's blood pressure response. In certain cases, healthcare providers have administered doses as high as 2.0 mcg/kg per minute or higher without encountering toxic effects. It is important to exercise caution or avoid the use of fenoldopam in patients with glaucoma.[15] Additionally, since fenoldopam is formulated with a solution containing sodium metabisulfite, patients with sulfite sensitivity should be carefully monitored.

Labetalol

Labetalol is an intravenous medication used for hypertensive emergencies, functioning as a dual blocker of both beta-adrenergic and alpha-adrenergic receptors. Its prompt onset of action makes it valuable in such critical situations.[24]. However, research suggests that labetalol may exhibit lower antihypertensive efficacy compared to nicardipine.[25]
Labetalol is considered safe to use in patients with active coronary disease as it does not increase heart rate. Nonetheless, caution must be exercised and its use avoided in individuals with conditions like asthma, chronic obstructive pulmonary disease, heart failure, bradycardia, or greater than first-degree heart block.
Prior adequate alpha blockade is essential before administering labetalol to patients with hyperadrenergic states, such as pheochromocytoma or cocaine/methamphetamine overdose, to prevent the potential elevation of blood pressure due to unopposed alpha-adrenergic activity.[26]
The dosing of labetalol can be given through a series of intravenous bolus injections or as a continuous infusion. The bolus dose typically ranges from 20 to 80 mg, with a maximum total dose of 300 mg. Infusion rates usually range from 0.5 to 2 mg per minute, with higher doses utilized in overweight or obese patients.[27]

Esmolol

Esmolol is a beta blocker known for its rapid onset of action and relatively selective effects on the cardiovascular system (28). It is quickly metabolized by blood esterases, resulting in a short half-life of about 9 minutes. This characteristic allows for rapid titration and adjustment of the medication dosage. Esmolol finds common use during anesthesia to prevent hemodynamic disturbances that may occur following intubation.[29]

Hydralazine

Hydralazine is a direct arteriolar vasodilator primarily employed in hypertensive emergencies, though it is not a preferred choice. It primarily affects arterial circulation and has minimal impact on venous circulation (30). Caution is advised when administering it to patients with underlying coronary disease or aortic dissection. To minimize reflex sympathetic stimulation, concurrent administration of a beta blocker is recommended.[31]
The hypotensive response to hydralazine is less predictable compared to other parenteral agents used for blood pressure control. Limited evidence supports its use in improving outcomes for hospitalized patients with hypertension, as it may also lead to hypotension. While its primary usage is evidenced in pregnant women, caution should be exercised due to the reported reduction in blood flow to the uterus and placenta.
Hydralazine is administered as an intravenous bolus, with an initial dose of 10 mg and a maximum dose of 20 mg. Its blood pressure-lowering effect begins within 10 to 30 minutes and typically lasts for two to four hours.[32]

Enalaprilat

Enalaprilat is an intravenous form of the angiotensin-converting enzyme (ACE) inhibitor called enalapril. The response to enalaprilat in terms of blood pressure reduction can be unpredictable and varies based on plasma volume and plasma renin activity.[33] Patients who are hypovolemic with high plasma renin activity are at a higher risk of experiencing an excessive drop in blood pressure. It is important to note that ACE inhibitors, including enalaprilat, are contraindicated in certain conditions such as pregnancy, severe renal artery stenosis with kidney ischemia, and severe hyperkalemia.[34]
The typical initial dose of enalaprilat ranges from 1.25 mg, with additional doses of up to 5 mg may be administered as needed every six hours. The onset of action occurs within 15 minutes, although the peak effect of enalaprilat may not be seen until four hours after administration. The duration of action spans from 12 to 24 hours, providing sustained blood pressure control.[35]

Phentolamine

Phentolamine, a nonselective alpha-adrenergic blocker, is primarily used to treat severe hypertension that is associated with increased catecholamine activity.[36] It finds application in conditions such as pheochromocytoma or tyramine ingestion in patients undergoing treatment with a monoamine oxidase inhibitor.[37] However, it should be noted that phentolamine is not more effective than other alpha-adrenergic blockers and may not be readily available in some medical centers. The administration of phentolamine is typically via intravenous bolus, with a usual dose ranging from 5 to 15 mg

as needed, to be repeated every 5 to 15 minutes. Once patients no longer require intravenous therapy, they may be transitioned to oral phenoxybenzamine.

Conclusion

In conclusion, hypertensive encephalopathy is a critical condition characterized by neurological dysfunction due to severely elevated blood pressure. It is most commonly associated with uncontrolled hypertension or abrupt discontinuation of antihypertensive medication. The pathophysiology involves vasogenic cerebral edema and potentially reversible posterior white matter lesions.

Prompt diagnosis and appropriate management are crucial in hypertensive encephalopathy to prevent further neurological damage and associated complications. Monitoring and controlling blood pressure levels play a central role in treatment, aiming for gradual reduction while avoiding abrupt drops to prevent cerebral ischemia. Various antihypertensive medications, such as nitroprusside, labetalol, or nicardipine, among others, are used in acute settings to achieve blood pressure control.

Besides blood pressure management, identifying and addressing underlying causes, such as renal dysfunction, electrolyte imbalances, or medication non-compliance, is vital. Additional interventions may be necessary in cases of specific etiologies, such as pheochromocytoma or renal artery stenosis. Close monitoring of neurological status, including mental status, visual function, and focal deficits, is essential to detect any worsening or improvement.

References:

1. Xie F, Cai Y, Huang L, Hao J, Ling T, Richard SA. Obstructive ureteric calculus with superimposed infections causing reversible posterior leukoencephalopathy syndrome: A case report. Medicine. 2021 Apr 4;100(16).
2. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovascular and brain metabolism reviews. 1990 Jan 1;2(2):161-92.
3. Schwartz RB. Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions. The neurologist. 2002 Jan 1;8(1):22-34.
4. Miller JB, Suchdev K, Jayaprakash N, Hrabec D, Sood A, Sharma S, Levy PD. New developments in hypertensive encephalopathy. Current hypertension reports. 2018 Feb;20:1-7.
5. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008 Jul 8;118(2):176-87.
6. Armstead WM. Cerebral blood flow autoregulation and dysautoregulation. Anesthesiology clinics. 2016 Sep 1;34(3):465-77.
7. Oppenheimer BS, FISHBERG AM. Hypertensive encephalopathy. Archives of Internal Medicine. 1928 Feb 1;41(2):264-78.
8. Price RS, Kasner SE. Hypertension and hypertensive encephalopathy. Handbook of clinical neurology. 2014 Jan 1;119:161-7.
9. Finnerty Jr FA. Hypertensive encephalopathy. The American journal of medicine. 1972 May 1;52(5):672-8.
10. Dinsdale HB. Hypertensive encephalopathy. Stroke. 1982 Sep;13(5):717-9.
11. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978 Sep 1;28(9):928-.
12. Williams O, Brust JC. Hypertensive encephalopathy. Current Treatment Options in Cardiovascular Medicine. 2004 Jun;6(3):209-16.
13. Donaldson JO. Eclamptic hypertensive encephalopathy. InSeminars in neurology 1988 Sep (Vol. 8, No. 03, pp. 230-233). © 1988 by Thieme Medical Publishers, Inc..
14. Pavlakis SG, Frank Y, Chusid R. Topical review: hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Journal of child neurology. 1999 May;14(5):277-81.
15. Chawla R, Smith D, Marik PE. Near fatal posterior reversible encephalopathy syndrome complicating chronic liver failure and treated by induced hypothermia and dialysis: a case report. Journal of Medical Case Reports. 2009 Dec;3(1):1-4.
16. Patel R, Ansari A, Grim CE. Prognosis and predisposing factors for essential malignant hypertension in predominantly black patients. The American journal of cardiology. 1990 Oct 1;66(10):868-9.
17. Sharifian M. Hypertensive encephalopathy. Iranian journal of child neurology. 2012;6(3):1.
18. Auer LM. The pathogenesis of hypertensive encephalopathy: experimental data and their clinical relevance with special reference to neurosurgical patients.
19. Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, Rana S, Vermunt JV, August P. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022 Feb;79(2):e21-41.
20. Mahfoud F, Böhm M, Bongarth CM, Bosch R, Schmieder RE, Schunkert H, Stellbrink C, Trenkwalder P, Vonend O, Weil J, Kreutz R. Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension. Der Kardiologe. 2019 Feb;13:17-23.
21. Chawla R, Smith D, Marik PE. Near fatal posterior reversible encephalopathy syndrome complicating chronic liver failure and treated by induced hypothermia and dialysis: a case report. Journal of Medical Case Reports. 2009 Dec;3(1):1-4.
22. Gifford Jr RW, Westbrook E. Hypertensive encephalopathy: mechanisms, clinical features, and treatment. Progress in Cardiovascular Diseases. 1974 Sep 1;17(2):115-24.
23. Vaughan CJ, Delanty N. Hypertensive emergencies. The Lancet. 2000 Jul 29;356(9227):411-7.
24. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1983 Jul 8;3(4):193-217.

25. Brogden RN, Heel RC, Speight TM, Avery GS. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978 Apr;15:251-70.
26. Richards DA, Prichard BN. Clinical pharmacology of labetalol. British Journal of Clinical Pharmacology. 1979;8(Suppl 2):89S.
27. Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. British journal of clinical pharmacology. 1976 Aug 1;3(4 Suppl 3):695-710.
28. Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clinical pharmacokinetics. 2012 Jun;51:347-56.
29. Wiest D. Esmolol: a review of its therapeutic efficacy and pharmacokinetic characteristics. Clinical pharmacokinetics. 1995 Mar;28(3):190-202.
30. Koch-Weser J. Hydralazine. New England Journal of Medicine. 1976 Aug 5;295(6):320-3.
31. Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane database of systematic reviews. 2011(11).
32. Magee LA, Cham C, Waterman EJ, Ohlsson A, Von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Bmj. 2003 Oct 23;327(7421):955.
33. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24.
34. Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. British journal of clinical pharmacolo gy. 1986 Apr;21(4):341-8.
35. Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. The Journal of Clinical Pharmacology. 1986 Jan;26(1):39-43.
36. Gould L, Reddy CV. Phentolamine. American Heart Journal. 1976 Sep 1;92(3):397-402.
37. Taylor SH, Sutherland GR, MacKenzie GJ, Staunton HP, Donald KW. The circulatory effects of intravenous phentolamine in man. Circulation. 1965 May;31(5):741-54.

How to cite this article: Saalim M, Ali U, Hypertensive Encephalopathy: A Comprehensive Review. Hypertens J. 2023; 9(2): 45-51.
Source of support: Nil, **Conflicts of interest:** None